Recombinant CDK4 antibody (N-Term)

Catalog No. ABIN7879592

This Rabbit Monoclonal antibody specifically detects CDK4 in IHC (p). It exhibits reactivity toward Human.

Quick Overview for Recombinant CDK4 antibody (N-Term) (ABIN7879592)

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CDK4 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CDK4-8351R

Product Details anti-CDK4 Antibody

Binding Specificity: N-Term

Purpose: Recombinant CDK4 Antibody

Purification: Protein A/G affinity

Immunogen: A recombinant fragment corresponding to the N-terminal of human CDK4 protein was used as the immunogen for the recombinant CDK4 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the recombinant CDK4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Aliquot the recombinant CDK4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CDK4

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Alternative Name: CDK4

Background: Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level. CCND1- CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth. CDK4 is highly expressed in highly differentiated and dedifferentiated liposarcomas, but rarely expressed in other benign liposarcomas and other sarcomas. CDK4 and MDM2 combined to differentiate between highly differentiated liposarcoma (+), dedifferentiated liposarcoma (+) and myxoid liposarcoma, pleomorphic liposarcoma, spindle lipoma, pleomorphic lipoma and other high-grade sarcomas.

UniProt: P11802

Pathways: Cell Division Cycle, Mitotic G1-G1/S Phases, Regulation of Cell Size